Clinical trial · Interventional
Heading Off Peripheral Neuropathy With Exercise
Pilot Randomized Study of Aerobic and Resistance Exercise for Women Undergoing Treatment for Breast Cancer With Taxanes.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Could not recruit total numbers needed. PI left institution.
Summary
Brief summary (as posted)
Chemotherapy for the treatment of breast cancer can affect nerves and muscles leading to loss of sensation in the hands and feet for feeling hot and cold, difficulty walking, and muscle weakness. This study will explore if exercises such as walking and strength training may prove helpful in preventing or lessening chemotherapy-induced peripheral neuropathy from chemotherapy, making the therapy easier to tolerate and increasing overall quality of life.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Chemotherapy | — | UNRESOLVED | — |
| Peripheral Nervous System Disorders | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aerobic/ Resistance Exercise Intervention | Behavioral | — | UNRESOLVED |
| Attention control | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Exercise
- description
- combination aerobic (walking) and resistance (strength training) exercise
- interventionNames
- Behavioral: Aerobic/ Resistance Exercise Intervention
- type
- SHAM_COMPARATOR
- label
- attention control
- description
- attention control with daily journal and cancer-related education
- interventionNames
- Behavioral: Attention control
Primary outcomes (1)
- measure
- effect size for reduction of neuropathic symptoms
- timeFrame
- Baseline, 4, 8 12, 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * age 19 or older with newly diagnosed Stage I-IIIa invasive breast cancer who are to be treated with a taxane-based chemotherapy regimen (with paclitaxel or docetaxel) and thus are at risk for the development of CIPN. Exclusion Criteria: * any disease (e.g. diabetes, HIV) that results in peripheral neuropathy; * any disease or disorder that results in muscle weakness (such as chronic fatigue syndrome, multiple sclerosis, spinal cord tumors or injuries, stroke, preexisting cardiopulmonary disease); * any disease or disorder that would preclude strength training exercises (such as bone metastasis, osteoporosis); * individuals with diagnosed lymphedema or advanced disease (\> Stage IIIa, or metastatic disease) at high risk for bone metastases and pathologic fracture will be excluded.
References
Publications (0)
Data not yet available